- Home
- AES vs LEGN Comparison
AES vs LEGN Comparison
Compare AES & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AES
- LEGN
- Stock Information
- Founded
- AES 1981
- LEGN 2014
- Country
- AES United States
- LEGN United States
- Employees
- AES N/A
- LEGN N/A
- Industry
- AES Electric Utilities: Central
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- AES Utilities
- LEGN Health Care
- Exchange
- AES Nasdaq
- LEGN Nasdaq
- Market Cap
- AES 7.1B
- LEGN 7.0B
- IPO Year
- AES 1991
- LEGN 2020
- Fundamental
- Price
- AES $12.21
- LEGN $27.78
- Analyst Decision
- AES Buy
- LEGN Strong Buy
- Analyst Count
- AES 7
- LEGN 13
- Target Price
- AES $12.86
- LEGN $75.67
- AVG Volume (30 Days)
- AES 15.5M
- LEGN 1.5M
- Earning Date
- AES 05-01-2025
- LEGN 05-13-2025
- Dividend Yield
- AES 5.76%
- LEGN N/A
- EPS Growth
- AES 146.43
- LEGN N/A
- EPS
- AES 1.83
- LEGN N/A
- Revenue
- AES $12,119,000,000.00
- LEGN $728,303,000.00
- Revenue This Year
- AES $4.10
- LEGN $65.96
- Revenue Next Year
- AES $2.95
- LEGN $52.55
- P/E Ratio
- AES $6.69
- LEGN N/A
- Revenue Growth
- AES N/A
- LEGN 112.46
- 52 Week Low
- AES $9.57
- LEGN $29.27
- 52 Week High
- AES $22.21
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- AES 65.04
- LEGN 29.61
- Support Level
- AES $10.19
- LEGN $30.25
- Resistance Level
- AES $12.67
- LEGN $33.30
- Average True Range (ATR)
- AES 0.42
- LEGN 1.78
- MACD
- AES 0.29
- LEGN -0.57
- Stochastic Oscillator
- AES 83.21
- LEGN 5.19
About AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio as of year-end 2023 totals over 35 gigawatts, including renewable energy (53%), gas (27%), coal (18%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.